SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
HUMA

Humacyte, Inc. (HUMA)

NASDAQ: HUMA · USD
Healthcare · Biotechnology
$0.45-$0.10 (-17.90%)
 
Market cap
$124M
Insider Score
Analyst consensus
Market Cap$123.73M-60.3%
Revenue (ttm)$2.40M
Net Income-$94.76M
EPS-$0.45
Shares Out277.80M
PE Ration/a
Forward PE-1.78
Dividendn/a
Ex-Dividend Daten/a
Volume5,771,034
Open$0.51
Previous Close$0.54
Day's Range$0.44 - $0.52
52-Week Range$0.34 - $1.52
Beta2.68
AnalystsBuy
Price Target$1.64(+268.58%)
Earnings DateNov 10, 2026

About HUMA

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Address
2525 East North Carolina Highway 54, Durham, NC, 27713, United States
Market Cap
124 million
Employees
184
Industrial Classification
Biotechnology

Humacyte, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
0th Percentile Overall Score
HUMA InsiderScore:23 / 99

Humacyte, Inc. scored higher than 0% of companies evaluated by InsiderBuying, and ranked 107th out of 110 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Humacyte, Inc. bought $5.6K of stock across 1 purchase in the last 90 days, the largest of them $5.6K.

Stake Increase

The average purchase added about 25% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceBalanced
Sold
$82.60K
Bought
$90.16K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy1 Hold0 SellAvg target $2.50 (+461.3%)

2 firms rating HUMA in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-18.05%
5 Days
-20.25%
1 Month
+7.75%
6 Months
-57.62%
1 Year
-60.27%

$HUMA stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of HUMA by members of U.S. Congress

Tommy TubervilleSenate / RPurchase$1.00K – $15.00KMar 21, 2024
Tommy TubervilleSenate / RPurchase$15.00K – $50.00KMar 21, 2024

Recently reported changes in HUMA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by HUMA's directors and management

Net Shares Purchased by Insiders−50k−25k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

HUMA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New HUMA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to HUMA from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from HUMA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
22.14
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
72

News check: FDA regulatory progress, 151% revenue surge in key product, expanding clinical evidence, and strong commercial adoption drive notably positive coverage.

Recent Insider Activity

Buys
5
Sells
2
Buy Value
$90.16K
Distinct Buyers
3

Insider Score Trend Over Time

-17.5 since Sep 23
0255075100Sep 23 — Insider Score 39.6Sep 24 — Insider Score 38.8Sep 25 — Insider Score 51.6Sep 26 — Insider Score 51.5Sep 27 — Insider Score 51.6Sep 28 — Insider Score 51.7Sep 29 — Insider Score 51.1Sep 30 — Insider Score 50.9Oct 1 — Insider Score 50.6Oct 2 — Insider Score 36.0Oct 3 — Insider Score 50.2Oct 4 — Insider Score 50.3Oct 5 — Insider Score 50.3Oct 6 — Insider Score 49.6Oct 7 — Insider Score 49.2Oct 8 — Insider Score 49.1Oct 9 — Insider Score 49.0Oct 10 — Insider Score 48.6Oct 11 — Insider Score 49.4Oct 12 — Insider Score 49.4Oct 13 — Insider Score 49.0Oct 14 — Insider Score 48.6Oct 15 — Insider Score 48.5Oct 16 — Insider Score 48.2Oct 17 — Insider Score 48.1Oct 18 — Insider Score 48.4Oct 19 — Insider Score 48.2Oct 20 — Insider Score 48.1Oct 21 — Insider Score 48.0Oct 22 — Insider Score 48.1Oct 23 — Insider Score 48.1Oct 24 — Insider Score 48.0Oct 25 — Insider Score 47.7Oct 26 — Insider Score 47.5Oct 27 — Insider Score 47.7Oct 28 — Insider Score 47.5Oct 29 — Insider Score 47.1Oct 30 — Insider Score 45.9Oct 31 — Insider Score 45.5Nov 1 — Insider Score 45.7Nov 2 — Insider Score 45.6Nov 3 — Insider Score 44.6Nov 4 — Insider Score 43.9Nov 5 — Insider Score 43.2Nov 6 — Insider Score 42.2Nov 7 — Insider Score 41.6Nov 8 — Insider Score 42.0Nov 9 — Insider Score 42.4Nov 10 — Insider Score 40.7Nov 11 — Insider Score 39.8Nov 12 — Insider Score 39.3Nov 13 — Insider Score 37.9Nov 14 — Insider Score 36.8Nov 15 — Insider Score 33.9Nov 16 — Insider Score 33.5Nov 17 — Insider Score 31.1Nov 18 — Insider Score 25.2Nov 19 — Insider Score 24.2Nov 20 — Insider Score 23.2Nov 21 — Insider Score 22.1Sep 23Oct 22Nov 21

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

SPXZMorgan Creek - Exos SPAC Originated ETF1.50%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.08%
IBBQInvesco Nasdaq Biotechnology ETF0.01%
IBBiShares Biotechnology ETF0.01%
BIBProShares Ultra Nasdaq Biotechnology0.01%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.